Effect of simultaneous blockade of AT1 and AT2 receptors on the NFκB pathway and renal inflammatory response  by Esteban, Vanesa et al.
Kidney International, Vol. 64, Supplement 86 (2003), pp. S33–S38
Effect of simultaneous blockade of AT1 and AT2 receptors on
the NFB pathway and renal inflammatory response
VANESA ESTEBAN, MO´NICA RUPEREZ, JUAN RODRIGUEZ VITA, ELSA SANCHEZ LO´PEZ,
SERGIO MEZZANO, JUAN JOSE´ PLAZA, JESU´S EGIDO, and MARTA RUIZ-ORTEGA
Laboratory of Vascular and Renal Pathology, Fundacio´n Jime´nez Dı´az, Universidad Auto´noma, Madrid, Spain; and
Universidad Austral, Valdivia, Chile
Effect of simultaneous blockade of AT1 and AT2 receptors on
the NFB pathway and renal inflammatory response.
Background. Angiotensin II (Ang II) is a cytokine that
participates in the inflammatory response. The nuclear factor
kappa B (NFB) is involved in the regulation of many immune
and inflammatory factors. Different works have shown that
both angiotensin II receptor type 1 (AT1) and type 2 (AT2) re-
ceptors are involved in the NFB pathway; however, some
aspects remain mysterious. AT1 antagonists increased plasma
Ang II levels that could bind to AT2, so understanding the
clinical importance of AT2 stimulation or inhibition is an inter-
esting unresolved point.
Methods. Experiments were done in wild-type (WT) and
AT1a receptor knockout mice that received subcutaneous Ang
II infusions (1000 ng/kg/min) for 3 days. Specific blockers of
AT1 (losartan 10 mg/kg/day) and AT2 (PD123319 30 mg/kg/
day) receptors were administered 1 day before and during Ang
II infusion. NFB activity was examined by electrophoretic
mobility assay and inflammatory (monocyte/macrophage) cell
infiltration by immunohistochemistry
Results. In WT mice, Ang II infusion caused renal NFB
activation that was partially diminished by either AT1 or AT2
antagonists. In AT1 knockout mice, Ang II also activated renal
NFB, which was only blocked by the AT2 antagonist. Both
Ang II–infused WT and AT1 knockout mice showed inflamma-
tory infiltration in tubulointerstitial areas that were suppressed
by the AT2, but not AT1, antagonist. Combined therapy of both
AT1 and AT2 antagonists blocked renal NFB activation and
inflammatory cell infiltration, both in WT and in AT1 knockout
mice.
Conclusion. Ang II, via AT1 and AT2 stimulation, leads to
NFB activation that was only blocked by combined therapy
with both antagonists. The participation of AT2 receptors in
the recruitment of inflammatory cells underscores the need
of future studies that evaluate the clinical usefulness of this
strategy.
Angiotensin II (Ang II) is a cytokine involved in the
regulation of cell growth and fibrosis [1]. Several works
have demonstrated that Ang II induces many pro-
inflammatory events, regulates immune cell responses,
and is involved in the pathogenesis of immune-mediated
renal diseases [2, 3–5].
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Two distinct subclasses of Ang II receptors, AT1 and
AT2, have been described [6, 7]. The well-known Ang
II actions (vasoconstriction, proliferation, and fibrosis)
are mediated by the activation of various signal-trans-
duction pathways via AT1. The biological functions and
molecular mechanisms of AT2 remain mysterious. AT2
signaling activates phosphatases and production of cer-
amides, arachinodate, and kinin/nitric oxide/cGMP, and
regulates apoptosis/inhibition of cell growth, vasodilata-
tion, and pressure natriuresis. This receptor is re-expressed
in pathologic situations involving tissue remodeling or
inflammation, including renal damage [6–8].
The nuclear factor kappa B (NFB) is important in the
regulation of the inflammatory response because it con-
trols many proinflammatory genes, including cytokines,
adhesion molecules, and chemokines [9]. Both in vivo
and in vitro Ang II activate NFB and up-regulate NFB-
related genes [2]. Recent works have demonstrated that
both AT1 and AT2 receptors activate the NFB pathway
[10–14]; however, important questions remain unresolved
[15, 16]. One such question is the biological significance
of AT2/NFB activation. Some data suggest that AT2 could
be involved in the inflammatory cell recruitment [11, 17]
and in the regulation of NFB activity in the kidney [11,
13, 14]. When AT1 is blocked, circulating Ang II levels
are increased, free Ang II could bind to AT2, and exert
some yet undefined functions with potential clinical im-
portance. The present studies were done to further inves-
tigate this issue, evaluating the role of Ang II receptors
in renal inflammation and the NFB pathway. For this
purpose we used AT1a receptor knockout mice and wild-
type (WT) mice that were given systemic Ang II infu-
sions, and the administration of selective nonpeptidic an-
tagonists for AT1 and AT2 receptors, investigating what
happened if both AT1 and AT2 receptors were blocked.
METHODS
Experimental design
Animals used were male WT (C57BL/6) and AT1a re-
ceptor knockout mice, with the same genetic back-
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ground. The AT1 knockout was generated by a homolo-
gous recombination method (from Dr. Sugaya, Tanabe
Seiyaku Corp., Osaka, Japan), and has been previously
used [4]. Ang II was given by subcutaneous osmotic
minipumps (Alza Corp., Cupertino, CA, USA), at a dose
of 1000 ng/kg/min. Control (saline-infused) animals of
the same age were also studied. Animals were sacrificed
at days 3 (N 8 in each group). Pharmacologic blockade
of Ang II receptors was done with the AT1 antagonist
losartan (10 mg/kg/day; drinking water) or the AT2 an-
tagonist PD123319 (30 mg/kg/day, subcutaneous osmotic
minipumps), or with a combination of both antagonists,
starting 24 hours before Ang II infusion and maintained
during the experimental period. The administered doses
are known to effectively block the corresponding recep-
tor [11]. Losartan was kindly provided by MSD (Madrid,
Spain), and PD123319 was obtained from Sigma Chemi-
cal Co. (St. Louis, MO, USA).
Morphology and immunohistochemistry
Paraffin-embedded sections were treated for each tech-
nique as described before [11]. Morphology was evalu-
ated by Masson’s staining and light microscopy. Inflam-
matory cell infiltration was characterized by monoclonal
antibodies against F4/80 antigen (Serotec, Raleigh, NC,
USA), present in murine monocytes/macrophages. Briefly,
sections were rehydrated, endogenous peroxidase and
unspecific binding were blocked, incubated with primary
antibodies, and revealed by standard methods. In each
experiment, negative control groups (omitting the pri-
mary antibody, or with an unrelated antibody) were in-
cluded. Immunohistochemical quantification for inflam-
matory cell infiltration was evaluated by image analysis
using a KZ 300 Imaging System 3.0 (Zeiss, Mu¨nchen-
Hallbergmoos, Germany). The percentage of the stained
area was calculated as the ratio of suitable binary thresh-
old image and the total field area. For each sample,
the mean staining area was obtained by analysis of 10
different fields (20), excluding glomeruli and vessels.
The staining score is expressed as percent positive area
in the total area under examination.
Determination of renal NFB activity
NFB activity was evaluated by binding protein ex-
tracts from renal cortex with an oligoconsensus NFB
and analyzed by electrophoretic mobility shift assay
(EMSA) [11].
Statistical analysis
Results are expressed as mean SEM. Significant dif-
ferences were evaluated with non-parametric Kruskal-
Wallis analysis of variance (ANOVA) tests using a com-
mercial statistical program (GraphPAD Instat, San Diego,
CA, USA). Differences were considered significant when
the two-tailed P values was 0.05.
RESULTS
Angiotensin II infusion activates renal NFB via AT1
and AT2 receptors
Systemic infusion of Ang II for 3 days increased NFB
DNA-binding activity in the kidney of WT mice (2.9-
fold vs. control; P  0.05, N  6, EMSA) (Fig. 1). The
AT1 antagonist diminished around 66% renal NFB acti-
vation, demonstrating that AT1 is involved in the NFB
pathway. In Ang II–infused AT1 knockout mice renal
NFB activity was increased but lower than in WT
(2-fold, N 6) (Fig. 1). The fact that AT1 knockout mice
still present activation of NFB suggests the existence
of an AT1-independent NFB activation. The contribu-
tion of AT2 receptors to the stimulation of NFB was
further studied with its antagonist. PD123319 diminished
renal NFB activity, both in WT (around 66% inhibition
vs. Ang II–infused mice) and AT1 knockout Ang II–
infused mice. These data demonstrate activation of the
AT2/NFB pathway. When both AT1 and AT2 receptors
were blocked, renal NFB activity was reduced to con-
trol levels (P  0.05 vs. Ang II; P  NS vs. control,
N  3).
AT2 antagonist diminished inflammatory cell infiltration
The inflammatory cell infiltration was examined by im-
munohistochemistry with a specific anti-F4/80 antibody
that recognizes murine monocytes/macrophages (Fig. 2).
In control animals, only a few cells with positive anti-
F4/80 immunostaining were observed. After 3 days of
Ang II infusion, kidneys of WT and of AT1 knockout
mice presented an important increase in the mean num-
ber of monocytes/macrophages in the interstitium, dis-
tributed in a focal manner. Interestingly, there were no
monocytes in the glomerular area, showing a clear differ-
ence with the Ang II infusion model in rats [11].
The effect of Ang II receptors blockade was evaluated.
Interestingly, in WT only, the AT2 antagonist, but not the
AT1, diminished renal inflammatory cell infiltration. Sim-
ilar effects were also observed in AT1 knockout, since the
numbers of monocytes/macrophages were decreased to
control levels by the AT2 antagonist PD123319 (Fig. 2).
In animals with combined therapy of PD123319 and lo-
sartan the number of monocytes was similar to control.
DISCUSSION
One of the molecular mechanisms elicited by Ang II
and that could play a key role in the inflammatory re-
sponse is the activation of the NFB pathway [2]. In this
work, we have demonstrated that in vivo Ang II activates
NFB via both AT1 and AT2 receptors, as shown by the
results of inhibition with the corresponding specific an-
tagonists. These data confirm our previous studies in the
rat model of Ang II infusion [11]. In vascular smooth mus-
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Fig. 1. Angiotensin II (Ang II) in vivo acti-
vates nuclear factor kappa B (NFB) via AT1
and AT2 receptors. Wild-type (WT) and AT1a
receptor-knockout mice were infused with
Ang II (1000 ng/kg/min) for 3 days and re-
ceived the specific AT1 antagonist losartan (10
mg/kg/day) or AT2 antagonist PD123319 (30
mg/kg/day) alone or in combination. (A ) Rep-
resentative electrophoretic mobility shift assay
(EMSA) experiment that shows 2 or 3 differ-
ent animals of each group. Specificity of the
reaction was demonstrated with a 100-fold ex-
cess of unlabeled NFB oligonucleotide (not
shown). (B ) Densitometric analysis of the re-
sults (mean  SEM of 4 to 6 animals in each
group) expressed as arbitrary units. *P 0.05
vs. control; #P  0.05 vs. Ang II infusion.
cle cells, glomerular mesangial cells, and endothelial cells,
NFB activation occurs both via AT1 and AT2 [10, 11,
14], while in tubuloepithelial cells it only occurs through
AT1 [11]. Studies using cells from AT1 knockout mice
have demonstrated that Ang II may activate NFB inde-
pendently of AT1, as found in the present studies in
the kidney of Ang II–infused AT1 knockout mice. The
existence of the AT2/NFB pathway has also been dem-
onstrated with the use of specific AT2 agonists, and more
recently by Wolf et al [14] in studies in COS7 cells trans-
fected with AT2 receptors and PC12 cells, which only
express AT2. In those studies, the activation of the NFB
pathway was demonstrated by DNA binding and by tran-
sient transfection experiments with a reporter plasmid
containing NFB promoter binding sites.
The molecular mechanisms and cellular responses of
Ang II receptors are not completely defined. AT1 regulates
vasoconstriction, cell proliferation, and production of cyto-
kines and extracellular matrix proteins [1, 6, 7]. In models
of renal injury, AT1 antagonists decrease proteinuria,
matrix accumulation, and the production of growth fac-
tors [1, 18]. The information provided by AT2 blockers
and AT2 knockout mice supports an important role for
the AT2 in the physiopathology of the kidney [6, 7, 19,
20]. Some Ang II responses could be mediated by both
AT1 and AT2 receptors, among them nitric oxide release,
collagen synthesis, -2-adrenoreceptor activity [21–23],
and, as discussed here, NFB activation.
The AT2/NFB pathway is likely involved in the regu-
lation of the recruitment of inflammatory cells in the kid-
ney. In this work, we have demonstrated that in Ang II–
infused mice, only AT2 blockade, but not AT1, reduced
the presence of monocytes in interstitial areas. More-
over, inflammatory cells were also observed in kidneys
of Ang II–infused AT1 knockout mice, which were also
only diminished by AT2 antagonist. In previous studies
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Fig. 2. Inflammatory cell infiltration in the kid-
ney of angiotensin II (Ang II)–infused mice.
The presence of monocytes/macrophages was
determined by immunohistochemistry with an
anti-F4/80 antibody. Figures show a represen-
tative animal of each group of wild type (A )
and AT1a receptor-knockout (B ) mice (mag-
nification 100). Computer image analysis of
monocyte/macrophage score in the kidney sec-
tions is demonstrated in (C ) that shows results
expressed as mean percent F4/80 positive area
of 4 to 6 animals for each group.
in Ang II–infused rats, we and others have observed glo-
merular and interstitial inflammation that was only abol-
ished by the AT2 antagonists [11, 17]. This anti-inflam-
matory effect of AT2 blockade may be mediated by the
down-regulation of the expression of chemokines in glo-
merular and tubulointerstital areas [11, 17, 24]. For ex-
ample, in glomerular endothelial cells Ang II increases
regulated upon activation, normal T cell expressed and
secreted (RANTES) expression via AT2 receptors [17].
Other works also support the hypothesis that Ang
II participates in the recruitment of inflammatory cells
into the kidney via AT2. Participation of AT2-mediated
responses may explain differences found in the inflam-
matory response between AT1 antagonists and angiotensin-
converting enzyme (ACE) inhibitors in some renal dis-
eases. In the model of unilateral ureteral obstruction in
rats, ACE inhibitors, but not AT1 antagonists, dimin-
ished monocyte/macrophage infiltration [25]; in anti-thy-
mocyte serum-induced nephritis, the AT1 blockers only
reduced inflammatory infiltration around 50% [26]. Sim-
ilarly, in vascular diseases, some data also suggest that
AT2 participate in the inflammatory response. Pressure
overload–induced cardiac hypertrophy was completely
suppressed in AT2 knockout mice [27], and studies on vas-
cular lesions in AT2 knockout mice have demonstrated
that AT2 mediates the effect of inflammation on vascular
smooth muscle cell proliferation [28]. Furthermore, in-
flammatory mediators, including interleukin-1 (IL-1),
insulin, interferon regulatory factors, and Ang II up-regu-
late AT2 expression [6, 29]. In several models of renal and
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vascular damage characterized by an inflammatory re-
sponse, AT2 over-expression has been described [2, 6, 8].
These data further strengthen the possibility that AT2
receptors are involved in the development of inflamma-
tory process in renal and vascular diseases.
The Ang II receptor subtype involved in the immune
and inflammatory response is not fully defined. Some
experimental studies have shown that AT1 antagonists
diminished several proinflammatory parameters, includ-
ing the cytokine interleukin-6 and adhesion molecules
[2]. Ang II could activate leukocytes, leading to adhesion
of these cells to the vascular endothelium and their mi-
gration into the vessel wall. Piqueras et al [30] have
demonstrated that AT1 and AT2 receptor inhibition at-
tenuated Ang II–stimulated leukocyte migration into rat
mesenteric venules, showing that only combination of
both receptor blockers returned all parameters to basal
levels. We have also observed that only using combined
treatment with AT1 and AT2 antagonists completely
blocks renal inflammatory infiltration and NFB activa-
tion in Ang II–infused mice. These data shows that the
blockade of both receptors is necessary to fully stop
the inflammatory response. In addition, Ang II can be
degraded to other metabolites that can cause some patho-
logic effects, although there is little evidence of these
mechanisms in vivo [31]. In this sense, we have also ex-
plored the possibility that other angiotensin-related pep-
tides may possess proinflammatory properties. Treat-
ment of cultured renal and mononuclear cells with the
NH2-terminal Ang II metabolite Ang III caused activa-
tion of NFB and activator protein-1 (AP-1) and in-
creased monocyte chemoattractant protein-1 (MCP-1)
[32]. The Ang III–induced NFB activation was mainly
via AT2 [13]. When AT1 is blocked Ang II levels are
increased and Ang peptides (Ang III, Ang IV, and Ang
1-7) can be formed [31]. These peptides, through binding
to their specific receptors, might be involved in the effects
of AT1 blockade. In this sense, Ang III through AT2 and
the NFB pathway could be involved in the inflamma-
tory response, Ang(1–7) (maybe through a specific re-
ceptor) may cause vasodilatation, and Ang IV, via the
AT4 regulate plasminogen activator inhibitor-1 (PAI-1)
expression [31], could participate in the pathogenesis of
vascular damage.
The clinical importance of the finding that AT2 block-
ade diminishes inflammatory cell infiltration and NFB
activation needs to be addressed in human studies. In
untreated patients with hypertension, the ACE inhibitor
enalapril decreased plasma levels of adhesion molecules
and MCP-1, while losartan did not significantly change
them [33]. Recent clinical trials in cardiovascular and
renal diseases have shown that the beneficial effect of
AT1 antagonists and ACE inhibitors is not entirely ex-
plained by lowering blood pressure, but are also due to
the inhibition of cellular Ang II actions [34–39]. Several
experimental studies in animals and preliminary clinical
studies indicate that the combination of both drugs may
be more beneficial than either drug alone in hyperten-
sion, cardiac insufficiency, post-myocardial infarction,
and type II diabetes. Large clinical trials are necessary
to further document the putative advantages of such a
combined therapy.
Several authors have defended the yin yang hypothe-
sis, suggesting a counterbalance effect of AT2 in the pres-
ence of AT1 blockers. They suggest that AT2 receptor
activation leads principally to opposite effects to that
observed when Ang II binds to AT1 receptors, including
vasodilatation and antiproliferative/apoptotic responses
[6]. However, experimental studies with Ang receptor
blockers and knockout mice have provided data that
contradicts this postulate and the beneficial effects of
two large clinical trials in heart failure can be explained
without ascribing a major protective role to the unopposed
activity of the AT2 receptor in the failing myocardium
[40]. Similar evidence was found in experimental models
of renal damage (Ang II infusion and unilateral ureteral
obstruction) that have demonstrated that AT1 antago-
nists only partially diminished NFB activation [11, 41].
Moreover, only when both AT1 and AT2 receptors are
blocked, tissue NFB activity is reduced to control levels,
showing that both receptors may be involved in this
molecular pathway. These data show that the beneficial
effects observed with AT1 antagonists cannot be attrib-
uted to stimulation of the AT2/NFB pathway, destroy-
ing the yin yang–counterbalance idea, at least, in relation
to NFB/inflammation in the kidney.
CONCLUSION
Further experimental studies are necessary to define
the role of Ang receptors in inflammatory and immune
processes. In the progression from the bench to bedside,
the ongoing clinical trials could afford important infor-
mation of the potential beneficial effects of the blockade
of AT1 or AT2 in human renal diseases.
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